A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

NCT ID: NCT06910306

Last Updated: 2025-12-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-01
• Study Completion Date: 2026-12-01

Brief Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma

Detailed Description

This is a Prospective Open label Single arm Multi-center interventional study. The study is designed to evaluate the Feasibility and Safety of DaRT seeds for the treatment of recurrent Glioblastoma.

A total of 10 subjects will be enrolled.

Eligible patients who meet inclusion/exclusion criteria (as assessed during the screening period) will be invited to the site for the procedure of DaRT seeds insertion and will return for a follow up visit every 2 months (+/- 7 days ) up to 12 months (4 ,6 , 8, 10 and 12 ). Survival F.U (after visit 11) will be done via phone calls every 2-3 months until (1) the start of new anti-cancer treatment, (2) disease progression or (3) death, whichever occurs first.

Conditions

Recurrent Glioblastoma; Recurrent Gliomas

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental: DaRT seeds

DaRT sources are inserted into the tumor according to a pre determined plan. The delivery of the DaRT Sources into the tumor is done by using a designated Alpha DaRT Applicator .

Group Type: EXPERIMENTAL

Device :DaRT seeds

Intervention Type: DEVICE

The sources are impregnated with a layer containing Ra-224 which is well fixated to the surface of the source. Ra-224 undergoes a series of decay events with each daughter product producing an alpha particle

Interventions

Device :DaRT seeds

The sources are impregnated with a layer containing Ra-224 which is well fixated to the surface of the source. Ra-224 undergoes a series of decay events with each daughter product producing an alpha particle

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Males and females ≥ 18 and ≤ 85 years of age
• Patients must have histologically confirmed diagnosis of WHO grade IV glioblastoma (including variants such as gliosarcoma, giant cell glioblastoma).
• Single, gadolinium-enhancing tumor recurrence ≤ 3cm in maximum diameter
• Patient not amenable for surgical resection due to any of the following but not limited reasons: patient refusal, medically ineligible, surgically too high risk due to tumor location in a deep and/or eloquent location.
• Prior history of central nervous system (CNS) radiation (standard dose) with 50.4-60 Gy delivered in 1.8 Gy-2.0 Gy fractions with concurrent temozolomide (if the patient has received a non-standard fractionation or radiation dose, such as 40 Gy in 15 fractions.
• Patients must have a time interval ≥4 months between completion of prior radiation and trial registration and have tumor progression per RANO criteria
• Patients must have a measurable disease per RANO criteria
• Estimated life expectancy is more than 6 months
• Target lesion amenable for coverage by the DaRT sources
• Patient must either have had recent subtotal surgery/biopsy following tumor recurrence (at least 6 weeks from trial registration) or must have shown unequivocal radiographic evidence for tumor progression by contrast-enhanced MRI scan within 21 days prior to trial registration. If surgery was performed, must have a post-operative MRI scan within 21 days prior to trial registration.
• Patients have recovered from prior therapy side effects and must be at least 4 weeks post administration of chemotherapies or investigational agents with the exception of nitrosureas (such as Carmustine, Fotemustine, Lomustine) which requires 42 days of washout.
• Karnofsky performance score (KPS) of at least 60 documented within 14 days prior to trial registration
• Patients must have adequate biological parameters as demonstrated by the following blood counts at initial screening obtained ≤ 14 days prior to starting treatment Absolute neutrophil count (ANC) ≥ 1.5 × 109/L Platelet count ≥ 100,000/mm3 (80 × 109/L) Hemoglobin (Hgb) ≥ 9 g/dL.
• Patients must have the following blood chemistry levels at initial screening obtained ≤ 14 days prior to starting treatment AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal range (ULN) Total bilirubin ≤ 1.5 × ULN
• Effective contraception must be used by both male and female patients while on the study and for up to 3 months following treatment
• Patient must have been informed about the nature of the study, and must have agreed to participate in the study, and signed the Informed Consent Form (ICF) prior to participation in any study-related activities

Exclusion Criteria

• Medical contraindication to MRI (cardiac devices are allowed if MRI compatible)
• More than 3 relapses per RANO criteria
• Acquired and or genetic clinical bleeding tendency
• Suspicious of infratentorial or leptomeningeal or intraventricular disease
• Concomitant chemotherapy or any other systemic therapy not allowed in the protocol
• Recent or current (within 6 weeks) therapy with VEF or a VEGFR inhibitor
• Immunocompromised state due to either transplant or AIDS
• Prior allergic reaction to the study drugs
• History of hypertensive crisis or hypertensive encephalopathy
• Uncontrolled hypertension (defined as either >150 mm/Hg for systolic and >90mm/Hg for diastolic)
• History of a non-healing wound, ulcer, gastrointestinal bleed (> grade 3), traumatic injury, or bone fracture within 90 days prior to registration Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT
• High probability of protocol non-compliance (in opinion of investigator)
• Pregnancy or lactation
• Collagenous diseases, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alpha Tau Medical LTD.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Ohio State University Medical Center

Columbus, Ohio, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Joshua Palmer, MD

Role: primary

joshua.palmer@osumc.edu

917-601-3414

Other Identifiers

CTP-GBM-01

Identifier Type: -

Identifier Source: org_study_id